Navigation Links
Omeros Corporation Reports First Quarter 2013 Financial Results
Date:5/10/2013

many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.OMEROS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)Three Months EndedMarch 31,20132012(unaudited)Revenue$
,095

$
,496Operating expenses:Research and development7,127

7,246General and administrative3,988

2,322Total operating expenses11,115

9,568Loss from operations(10,020)

(8,072)Investment income6

12Interest expense(587)

(494)Other income, (expense) net112

(341)Net loss$
(10,489)

$
(8,895)Basic and diluted net loss per common share$
(0.40)

$
(0.40)Weighted-average shares used to compute

basic and diluted net loss per common share25,908,153

22,434,903OMEROS CORPORATIONCONSOLIDATED BALANCE SHEET DATA(In thousands)March 31,December 31,20132012Cash and cash equivalents and short-term investments

$
3,316

$
22,350Total assets

17,693

26,575Total notes payable

20,197

20,103Total current liabilities

10,585

9,318Accumulated deficit

(225,066)

(214,577)Total shareholders' equity (deficit)

(15,864)

(6,531) 


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
2. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
3. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
4. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
5. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
6. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
8. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
9. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
10. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
11. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... entitled " Lovetraction Lines ." It's for women interested in improving their love ... desire. The course, which officially launched to the public early this morning, has ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association ... and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to ... will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider of ... announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency the ... 24/7 Care At Home’s agency is one of three top Orange County agencies to ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Western ... success of the 2015 Special Olympics World Games, the largest sports and humanitarian event ... the 1984 Olympic Games. , The World Games, held July 25 through August 2, ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... oral cancer, which a dentist could perform by simply using ... set to be developed by researchers at the University of ... The international research team, involving scientists in Sheffield, has been ... to develop the test, which could provide an accurate diagnosis ...
... available in French . Inhibiting prostate cancer ... governs tumour growth A kinase is a type of ... proteins required for cell growth and maintenance, and researchers have ... developing prostate cancer. "It,s known as Mnk, and although it ...
... College of Nursing has been awarded a $753,817 grant ... Health Resources and Services Administration (HRSA), to prepare advanced ... high quality healthcare in rural and medically underserved urban ... to i-LEAD, Innovation in Leadership and Administration in Nursing ...
... Comprehensive Cancer Center and the departments of Chemistry ... uncovered a role for an essential cell protein ... "power plant" of the cell. The import ... for the replication, transcription and translation of the ...
... is twofold, as the patients not only suffer from ... called phantom pain. Unlike bodily wounds which will eventually ... a lifetime. "Phantom pain is very difficult to treat", ... "Mostly they prove to be highly therapy-resistant", the Professor ...
... , THURSDAY, Aug. 5 (HealthDay News) -- While maintaining ... of heart disease and diabetes, being overweight may actually ... researchers say. This new finding suggests that overweight ... open-angle glaucoma (POAG), one of the most common age-related ...
Cached Medicine News:Health News:New 'dentist' test to detect oral cancer will save lives 2Health News:New 'dentist' test to detect oral cancer will save lives 3Health News:Inhibiting prostate cancer without disturbing regular body processes 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 2Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 3Health News:Prosthesis with information at its fingertips 2Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: